The second domestic "recombinant Lai Lui insulin injection" was reported to the market.

On June 28, CDE's official website showed that the application submitted by Jiangsu Wanbang for the listing of "Recombinant Lai Lu insulin injection" was submitted by the Drug Review Centerrecombinant insulin is a new type of insulin analogue, which acts quickly, the duration of action is shorter, and is more in line with the insulin secretion curve during the physiological meal, and its formulation recombins the insulin injection fluid, the sein-zinc recombinant insulin mix injection (25R) and the thin protein zinc recombinant insulin mixture injection (50R) can better control blood sugar and reduce the occurrence of hypoglycemiarecombinant recombinant insulin injection stoulogy manufacturer Lilly, a product called Humalog, was approved by the U.SFDA in April 1996 for the treatment of diabetes, and was listed in China in 2005The fine protein zinc recombinant insulin mixinjection injection (25R), called Humalog Mix25, was approved by the FDA in December 1999 for the treatment of diabetes and was launched in China in 2010The fine protein zinc recombinant insulin mix injection (50R), called Humalog Mix50, was approved by the FDA in December 1999 for the treatment of diabetes and was launched in China in 2008According to theInsight database, in addition to the original study, only the recombinant insulin and its composition of the hybrid insulin of Ganli Pharmaceuticals recombinant Recombinant Recombinant Insulin Injection and Semenprotein Zinc Recombinant Recombinant Recombinant Recombinant Insulin Injection (25R) were approved for listing in 2006 and 2014, respectivelypublic data show that in 2019, domestic restructuring of lai's insulin and its mixed insulin sales reached 1.66 billion yuan, of which the original research manufacturer Lilly market share reached 91%, the rest of the market attributed to GanLi Pharmaceuticalsamong the, the oil protein zinc recombinant recombination of insulin mixed injections sales, accounting for 85% of all recombinant insulin salesInsight's database shows that the refined protein zinc recombinant insulin-mixed injection (50R) in Wanbang, Jiangsu Province, is currently in Phase 3 clinical phase and is expected to be listed soonthe penetration rate of three generations of insulin is low, public data show that only 2% of patients with diabetes use insulin drugs to control blood sugar, and this proportion in the United States is about 30%, so China's insulin market has a lot of potential, especially insulin drugsAt present in the domestic has been listed in the insulin-like drugs are mostly the original research monopolyPhoto Source: China-Thai Securities Research InstituteInsight's database shows that, in addition to the current listing of the group LaiLu insulin, Jiangsu Wanbang's research and development of recombinant insulin glycol also submitted a listing application in March this year.